BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Boserolimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Boserolimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04165070-2106@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Boserolimab: Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Boserolimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: K
 EYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3
 475) With or Without Chemotherapy When Used With Investigational Agents in
  Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (N
 SCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion: 13 Februa
 ry 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/boserolimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0416
 5070
URL:https://assetmemo.bio/drug/boserolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
